CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events
A study to assess the efficacy of once daily atorvastatin 10 mg versus placebo on cardiovascular endpoints in patients with non-insulin-dependent diabetes mellitus (NIDDM) who have a history of either hypertension, retinopathy, microalbuminuria, macroalbuminuria, or who currently smoke, but who do not have established corornary heart disease or other macrovascular disease.
Major Coronary Event
Coronary Artery Bypass Graft
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Prevention
|Official Title:||A Double Blind Placebo Controlled Study of Atorvastatin as Prevention of CHD in High Risk Patients With Non-Insulin Dependent Diabetes Mellitus (Collaborative Atorvastatin Study - CARDS)|
- Time from randomization to the occurrence of a primary clinical endpoint
- i.e. major coronary event or CABG or other coronary revascularization procedure
- or unstable angina or resuscitated cardiac arrest or stroke.
- The incidence rate of a primary clinical and endpoint; the time from randomization
- to the occurrence of and the incidence rate of other parameters e.g. total
- mortality, any cardiovascular event, new PVD etc. and the percent change from
- baseline in various lipid and lipoprotein parameters.
|Study Start Date:||January 1997|
|Estimated Study Completion Date:||February 2004|
Show 135 Study Locations
|Study Director:||Pfizer CT.gov Call Center||Pfizer|